My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

38.05 +3.56 (+10.32%)
Streaming Delayed Price Updated: 11:05 AM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
From Scholar Rock
Via Business Wire
Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock to Present at Upcoming Healthcare Conferences
From Scholar Rock
Via Business Wire
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
From Scholar Rock
Via Business Wire
Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation
From Scholar Rock
Via Business Wire
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress
From Scholar Rock
Via Business Wire
Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference
From Scholar Rock
Via Business Wire
48 Biggest Movers From Yesterday
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized... 
Via Benzinga
Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer
From Scholar Rock
Via Business Wire
Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference
From Scholar Rock
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Arcturus Therapeutics (NASDAQ:ARCT) stock moved upwards by 29.05% to $44.73 during Tuesday's regular session. As of 12:35 EST, Arcturus Therapeutics's... 
Via Benzinga
Scholar Rock Announces Leadership Change
From Scholar Rock
Via Business Wire
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress
From Scholar Rock
Via Business Wire
Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting
From Scholar Rock
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 248.41% to $7.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $93.4... 
Via Benzinga
Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting
From Scholar Rock
Via Business Wire
Scholar Rock to Present at Upcoming Healthcare Conferences in June
From Scholar Rock
Via Business Wire
42 Stocks Moving In Tuesday's Mid-Day Session
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 28.4% to $10.17 following reports indicating equipment billings increased 50% in April compared to the prior year's... 
Via Benzinga
25 Stocks Moving in Tuesday's Pre-Market Session
Gainers U.S. Well Services, Inc. (NASDAQ: USWS) rose 30.5% to $1.25 in pre-market trading after the company reported commitment to becoming all-electric hydraulic facturing... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Rise Ahead Of Economic Reports
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Nasdaq surged over 1% in the previous session. Investors are awaiting earnings results from... 
Via Benzinga
7 Stocks Moving In Monday's After-Hours Session
Gainers Scholar Rock (NASDAQ: SRRK) shares are trading higher after the company announced it received FDA Fast Track designation for apitegromab for the treatment of patients... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers OptiNose (NASDAQ:OPTN) stock rose... 
Via Benzinga
Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
From Scholar Rock
Via Business Wire
Scholar Rock to Present Trials in Progress Poster for SRK-181 DRAGON Phase 1 Clinical Trial at the American Society of Clinical Oncology Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy
From Scholar Rock
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.